Allogene Therapeutics Receives FDA RMAT Status for Cema-Cel
SOUTH SAN FRANCISCO, Calif., July 29, 2026 Allogene Therapeutics announced that the U.S. Food and Drug Administration (FDA) has...
LBCL
Advertisement
Roche Secures FDA sBLA Acceptance for Lunsumio VELO Combination
BASEL, Switzerland, June 18, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental...
Lyell Immunopharma Showcases Updated Ronde-Cel Data at EHA 2026
SOUTH SAN FRANCISCO, Calif., June 12, 2026 Lyell Immunopharma, Inc. announced updated safety and translational data for rondecabtagene autoleucel...
Allogene Therapeutics Reports Strong ALPHA3 Trial Data
South San Francisco, California | April 13, 2026 Allogene Therapeutics has announced encouraging interim results from its pivotal Phase...
Allogene to Reveal ALPHA3 CAR-T Trial Data Soon
South San Francisco, California | April 10, 2026 Allogene Therapeutics has announced that it will present the interim futility...
Advertisement
